NCT04068610 2026-03-02
COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
MedImmune LLC
Phase 1/2 Active not recruiting
Clinical Trials
10 trialsNCT06106308 2026-01-12
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
Cardiff Oncology
Phase 2 Active not recruiting
NCT05108428 2026-01-08
Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Active not recruiting
NCT06838338 2026-01-08
JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC
Peking University Cancer Hospital & Institute
Phase 1 Active not recruiting
NCT07243288 2025-11-21
RADIOPAN
Assistance Publique - Hôpitaux de Paris
Active not recruiting
NCT03904043 2025-10-23
NOM-ERA
Washington University School of Medicine
Phase NA Active not recruiting
NCT04595266 2025-09-29
LIVERPEARL
Grupo Espanol Multidisciplinario del Cancer Digestivo
Phase 2 Active not recruiting
NCT04919226 2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3 Active not recruiting
NCT05712356 2025-06-06
BOLSTER
Lisata Therapeutics, Inc.
Phase 2 Active not recruiting
NCT03548961 2025-04-04
Organ Preservation in Early Rectal Cancer Patients
Fox Chase Cancer Center
Phase 2 Active not recruiting